» Articles » PMID: 12796605

Translocation (11;15;19): a Highly Specific Chromosome Rearrangement Associated with Poorly Differentiated Thymic Carcinoma in Young Patients

Overview
Journal Am J Clin Oncol
Specialty Oncology
Date 2003 Jun 11
PMID 12796605
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Thymic carcinoma is a rare epithelial neoplasm of the thymus. The presence of a specific chromosomal abnormality may augment diagnosis and therapeutic stratification. We report a 15-year-old boy diagnosed with thymic carcinoma who presented with a large anterior mediastinal mass, pleural effusion, and bone metastasis. The pleural fluid, cytology, bony lesions, and bone marrow were examined and chromosomal studies were performed. Histologic and immunohistochemical studies confirmed a poorly differentiated squamous cell type of thymic carcinoma. The karyotype of the pleural fluid at the time of diagnosis revealed a complex three-way translocation t(11;15;19)(p15;q12;p13.3). The constitutional karyotype was 46,XY. Five months after diagnosis, a bone marrow aspirate demonstrated tetraploidy with all translocation chromosomes in duplicate, as well as an unbalanced rearrangement involving chromosome 1: 92,XXYY,t(11;15;19)(p15;q12;p13.3)x2[15]/92,XXYY,idem,add(1)(qter)[5]. Despite aggressive multiagent chemotherapy, the patient's condition progressed with bone marrow disease and he died 6 months after diagnosis. Several case reports of a similar chromosomal abnormality have been reported for thymic carcinoma in young patients with poor outcome. This karyotypic abnormality appears to mark a cohort of patients with thymic carcinoma who have a poor prognosis despite aggressive chemotherapy.

Citing Articles

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes.

Huang Y, Durall R, Luong N, Hertzler H, Huang J, Gokhale P bioRxiv. 2023; .

PMID: 37645799 PMC: 10461970. DOI: 10.1101/2023.08.15.553204.


Cell state-dependent chromatin targeting in NUT carcinoma.

Alekseyenko A, Zee B, Dhoondia Z, Kang H, Makofske J, Kuroda M bioRxiv. 2023; .

PMID: 37131839 PMC: 10153199. DOI: 10.1101/2023.04.18.537367.


Cell state-dependent chromatin targeting in NUT carcinoma.

Alekseyenko A, Zee B, Dhoondia Z, Kang H, Makofske J, Kuroda M Genetics. 2023; 224(3).

PMID: 37119804 PMC: 10691748. DOI: 10.1093/genetics/iyad083.


NUT Midline Carcinoma: A Rare Solid Tumour Characterized by Chromosome Rearrangement.

Zhang H, Kong W, Liang W Evid Based Complement Alternat Med. 2022; 2022:3369895.

PMID: 35832518 PMC: 9273375. DOI: 10.1155/2022/3369895.


Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.

Shiota H, Alekseyenko A, Wang Z, Filic I, Knox T, Luong N Mol Cancer Res. 2021; 19(11):1818-1830.

PMID: 34285087 PMC: 8568634. DOI: 10.1158/1541-7786.MCR-21-0259.